Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Burundi.
Press releases published on July 7, 2025
Corza Medical Announces the Launch of the Expanded Onatec Ophthalmic Suture Portfolio
GlobeNewswire
·
July 7, 2025
PARSIPPANY, New Jersey, July 07, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global medical technology company, today announced the launch of its expanded Onatec Ophthalmic Suture Portfolio. This marks a significant extension of the product range, …
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
GlobeNewswire
·
July 7, 2025
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July …
Nudj Health Appoints Dr. Padmaja Patel as Chief Medical Officer to Advance Lifestyle Medicine Services
GlobeNewswire
·
July 7, 2025
PASADENA, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Nudj Health, the leading AI-powered lifestyle medicine services company, is proud to announce the appointment of Dr. Padmaja Patel as Chief Medical Officer of Lifestyle Medicine Services. In this role, Dr …
Synfini Adds $8.9 Million Discovery Funding to Speed Small Molecule Drug Development
GlobeNewswire
·
July 7, 2025
MENLO PARK, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Synfini, Inc., a trailblazer in AI-driven chemistry automation, today announced a $8.9 million expansion of its round, led by JSL Health Capital and supported by a strong syndicate of early-stage …
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
GlobeNewswire
·
July 7, 2025
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Ophthalmology Drugs Market to Reach $26.28 Billion by 2030—Vision Care Becomes a Strategic Growth Pillar | MarketsandMarkets™.
GlobeNewswire
·
July 7, 2025
Delray Beach, FL, July 07, 2025 (GLOBE NEWSWIRE) -- What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at a resilient CAGR of …
Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment
GlobeNewswire
·
July 7, 2025
THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has …
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
GlobeNewswire
·
July 7, 2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 ( …
Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025
GlobeNewswire
·
July 7, 2025
MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire’s management team will host a …
Collegium Announces $150 Million Share Repurchase Program
GlobeNewswire
·
July 7, 2025
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board …
Novel Digital Test Provides Revolutionary Tool to Assess Brain Chemistry
GlobeNewswire
·
July 7, 2025
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- For the first time, a study shows a digital assessment can provide a scientific measure of acetylcholine – a key brain chemical whose decline signals the progression of cognitive impairment and Alzheimer’s …
Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
GlobeNewswire
·
July 7, 2025
Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through Gero's AI-driven human data-first platform Accelerating the creation of innovation by combining Gero's …
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
GlobeNewswire
·
July 7, 2025
SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Théa (“Théa”) announced an exclusive license and commercialization agreement for Théa to register and commercialize LNZ100 for …
Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France
GlobeNewswire
·
July 7, 2025
FORT MILL, S.C., July 07, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced today that it …
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire
·
July 7, 2025
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed …
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
GlobeNewswire
·
July 7, 2025
ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today …
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
GlobeNewswire
·
July 7, 2025
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain Tividenofusp alfa leads company’s broader …
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
GlobeNewswire
·
July 7, 2025
ART12.11, the Patented CBD:TMP Cocrystal, Demonstrates Potent Antidepressant-Like Activity and Cognitive Benefits Over Leading SSRI Data Being Presented at the 35th Annual International Cannabinoid Research Society Symposium SOLANA BEACH, Calif., July 07, …
Medicines for Poland Announces: Without pharmaceutical factories Europe will lose any war
GlobeNewswire
·
July 7, 2025
BRUSSELS, July 07, 2025 (GLOBE NEWSWIRE) -- The need to establish a fund under the EU budget to support the production of critical medicines in Europe is a conclusion drawn from an analysis of the impact of the war on the availability of medicines in …
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
GlobeNewswire
·
July 7, 2025
8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240mg Q8W …